Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.
Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.
Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.
Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.
Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.
Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.
Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.
Bristol Myers Squibb (NYSE:BMY) has awarded five biotech startups with the 2021 Golden Ticket, granting them a year of lab space and support to foster innovation. The winners include RADD Pharmaceuticals, Rubik Therapeutics, Waypoint Bio, Altay Therapeutics, and VastBiome, each selected to advance research in various therapeutic fields. This initiative aims to stimulate the growth of life science startups and enhance collaborations within scientific communities, aligning with BMY's commitment to developing new medicines for serious diseases.
Bristol Myers Squibb (NYSE:BMY) announced positive results from the Phase 2 AXIOMATIC-TKR study, showcasing that the investigational oral agent milvexian effectively reduces venous thromboembolism (VTE) risk post-total knee replacement without increasing bleeding risks compared to enoxaparin. No major bleeding events occurred in the milvexian cohort. The trial demonstrated a significant dose-response relationship, with milvexian reducing VTE rates to 12% versus a benchmark of 30%. These findings support further exploration of milvexian's therapeutic potential.
Bristol Myers Squibb has launched the Could It Be HCM? campaign to raise awareness about hypertrophic cardiomyopathy (HCM), a chronic heart condition affecting 1 in 200 to 1 in 500 people. The campaign aims to educate the public about symptoms and encourage discussions with healthcare providers. Notably, an estimated 85% of HCM cases remain undiagnosed in the U.S. Professional basketball player Jared Butler, who has HCM, will share his experience to promote the campaign. The initiative includes resources found at CouldItBeHCM.com.
Bristol Myers Squibb (NYSE: BMY) announced its participation in the Wolfe Research Virtual Healthcare Conference, set for November 17, 2021, at 8:45 a.m. EST. CEO Giovanni Caforio will engage in a fireside chat, addressing company-related questions. Investors and the public can listen to the live webcast through the company’s investor relations website, with a recorded edition available later the same day. This event highlights BMY’s commitment to transparency and investor engagement.
Bristol Myers Squibb (NYSE: BMY) presented comprehensive research on its cardiovascular portfolio at the American Heart Association's annual Scientific Sessions from November 13-15, 2021. Key presentations included results from the AXIOMATIC-TKR study, exploring milvexian's efficacy in total knee replacement surgery, and analyses on mavacamten for obstructive hypertrophic cardiomyopathy. Researchers emphasized commitment to advancing treatment options for cardiovascular disease, a leading global health issue.
Bristol Myers Squibb (NYSE: BMY) announced that its Phase 3 CheckMate -816 trial successfully met the primary endpoint of improved event-free survival (EFS) in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC). The combination of Opdivo (nivolumab) and chemotherapy showed significant EFS benefits compared to chemotherapy alone in a prespecified interim analysis. This is the first Phase 3 trial with an immunotherapy-based combination to demonstrate substantial efficacy in a neoadjuvant setting, marking a pivotal advancement in the treatment of NSCLC.
Bristol Myers Squibb (NYSE: BMY) announced a significant presence at the 63rd ASH Annual Meeting, showcasing research on hematologic diseases, including data from over 80 studies. Key presentations include results from the Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel) against standard care for relapsed or refractory large B-cell lymphoma and new findings on CELMoD therapies like iberdomide. The company highlights its commitment to innovation in treatments for multiple myeloma, lymphoma, and myeloid diseases aimed at improving patient outcomes.
Bristol Myers Squibb (NYSE:BMY) showcased its commitment to rheumatology by presenting significant data on Orencia and deucravacitinib at the American College of Rheumatology (ACR) Convergence 2021. The presentations covered 29 studies, with key findings revealing that patients treated with Orencia showed improved disease activity scores in rheumatoid arthritis, especially among seropositive patients. Additionally, deucravacitinib, an oral TYK2 inhibitor, demonstrated promising results in the treatment of psoriatic arthritis, highlighting the company’s focus on innovative therapies for immune-mediated diseases.
Bristol Myers Squibb (NYSE:BMY) reported third quarter 2021 revenues of $11.6 billion, marking a 10% year-over-year increase. The GAAP earnings per share (EPS) was $0.69, a 16% decline, while non-GAAP EPS rose 23% to $2.00. The company's growth was driven by strong sales of Revlimid, Eliquis, and new products. Key regulatory advancements include FDA priority review for the relatlimab and nivolumab combination in melanoma. Updated full-year guidance indicates a reduction in GAAP EPS expectations to $2.68 - $2.83 and non-GAAP EPS to $7.40 - $7.55.
Bristol Myers Squibb (BMY) has announced a rescheduled earnings conference call to discuss its third quarter 2021 results. The call will take place on October 27, 2021, at 10:00 a.m. ET. Company executives will review financial results and address investor inquiries. A live webcast of the call will be accessible at investor.bms.com, and a replay will be available from 1:30 p.m. ET on October 27 through 1:30 p.m. ET on November 10, 2021.
FAQ
What is the current stock price of Bristol-Myers Squibb Co. (BMY)?
What is the market cap of Bristol-Myers Squibb Co. (BMY)?
What is Bristol-Myers Squibb's core business?
Where is Bristol-Myers Squibb headquartered?
What was Bristol-Myers Squibb's revenue for fiscal 2022?
What is a significant focus area for Bristol-Myers Squibb?
How much of Bristol-Myers Squibb's total sales come from the U.S. market?
What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?
What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?
What is SpliceCore®?
When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?
What is Bristol-Myers Squibb's mission?
